{"id":1573,"date":"2019-07-22T09:52:23","date_gmt":"2019-07-22T09:52:23","guid":{"rendered":"https:\/\/healthrights.mk\/?p=1573"},"modified":"2021-12-24T09:52:51","modified_gmt":"2021-12-24T09:52:51","slug":"who-recommends-dolutegravir-as-preferred-hiv-treatment","status":"publish","type":"post","link":"https:\/\/healthrights.mk\/?p=1573","title":{"rendered":"WHO recommends dolutegravir as preferred HIV treatment"},"content":{"rendered":"<p><em><strong>\u0418\u0437\u0432\u043e\u0440: \u0421\u0432\u0435\u0442\u0441\u043a\u0430 \u0437\u0434\u0440\u0430\u0432\u0441\u0442\u0432\u0435\u043d\u0430 \u043e\u0440\u0433\u0430\u043d\u0438\u0437\u0430\u0446\u0438\u0458\u0430 \u2013 22.07.2019<\/strong><\/em><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/healthrights.mk\/images\/Vesti\/2019\/07.2019\/1\/WHO%20recommends%20dolutegravir.jpg\" border=\"0\" \/><\/p>\n<p>Based on new evidence assessing benefits and risks, WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.<\/p>\n<p>DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance.<\/p>\n<p><a title=\"Read the press release\" href=\"https:\/\/www.who.int\/news-room\/detail\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations\" target=\"_blank\" rel=\"noopener\"><strong>Read the press release<\/strong><\/a><\/p>\n<p><a title=\"More about HIV\" href=\"https:\/\/www.who.int\/hiv-aids\/latest-news-and-events\/why-the-hiv-epidemic-is-not-over\" target=\"_blank\" rel=\"noopener\"><strong>More about HIV<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0418\u0437\u0432\u043e\u0440: \u0421\u0432\u0435\u0442\u0441\u043a\u0430 \u0437\u0434\u0440\u0430\u0432\u0441\u0442\u0432\u0435\u043d\u0430 \u043e\u0440\u0433\u0430\u043d\u0438\u0437\u0430\u0446\u0438\u0458\u0430 \u2013 22.07.2019 Based on new evidence assessing benefits and risks, WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of&hellip;<\/p>\n","protected":false},"author":1,"featured_media":1574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"post_series":[],"class_list":["post-1573","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vesti","entry","has-media"],"_links":{"self":[{"href":"https:\/\/healthrights.mk\/index.php?rest_route=\/wp\/v2\/posts\/1573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthrights.mk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthrights.mk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthrights.mk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthrights.mk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1573"}],"version-history":[{"count":1,"href":"https:\/\/healthrights.mk\/index.php?rest_route=\/wp\/v2\/posts\/1573\/revisions"}],"predecessor-version":[{"id":1575,"href":"https:\/\/healthrights.mk\/index.php?rest_route=\/wp\/v2\/posts\/1573\/revisions\/1575"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthrights.mk\/index.php?rest_route=\/wp\/v2\/media\/1574"}],"wp:attachment":[{"href":"https:\/\/healthrights.mk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthrights.mk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthrights.mk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1573"},{"taxonomy":"post_series","embeddable":true,"href":"https:\/\/healthrights.mk\/index.php?rest_route=%2Fwp%2Fv2%2Fpost_series&post=1573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}